Opthea Limited OPT
Set alert
At close · Apr 1
- Open
- 3.41
- Prev close
- 3.41
- Mkt cap
- 571.73M
- Vol
- 3.02K
- Avg vol
- 28.93K
- EPS
- -2.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.41
- High
- 3.41
- Forward P/E
- -1.95
- Beta
- 1.54
- Short ratio
- 2.45
- Inst. own
- 3.57%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 29, 2024
- 50-d avg
- 3.91
- 200-d avg
- 3.26
- 1y target
- 12.17
3M chart
Signals (8)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 24, 2025 | 1 year ago |
| SMA: Bearish | Mar 4, 2025 | 1 year ago |
| SMA: Bearish | Mar 4, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 25, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 12, 2025 | 1 year ago |
| RSI: Overbought | Feb 5, 2025 | 1 year ago |
Key statistics
- Market cap
- 571.73M
- Enterprise value
- 4.14B
- Trailing P/E
- 0.00
- Forward P/E
- -1.95
- PEG ratio
- 0.00
- Price / sales
- 2183.37
- Price / book
- 0.00
- EPS (TTM)
- -2.76
- Beta
- 1.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 261.86K
- Revenue growth
- -68.30%
- Free cash flow
- -94.87M
- Total cash
- 172.47M
- Total debt
- 200.63M
- Return on equity
- 0.00%
- Shares outstanding
- 153.89M
- Short % of float
- 0.06%
- 50-day average
- 3.91
- 200-day average
- 3.26
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 12.17
- Target (high)
- 18.00
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 29, 2024
Expected Aug 29, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 29, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Sep 12, 2023 | Jun 1, 2023 | -1.28 | — | — | — |
| Aug 29, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 13, 2023 | Oppenheimer | main | Outperform | Outperform |
| Aug 1, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2023 | EF Hutton | reit | Buy | Buy |
| Apr 17, 2023 | EF Hutton | init | — | Buy |
| Mar 13, 2023 | Oppenheimer | main | — | Outperform |
About Opthea Limited
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- opthea.com
News
- Cavendish backs Optima Health after interim update shows 60% revenue growth and lower debt
- Optima Health revenue rises 60% after PAM Healthcare acquisition
- Cavendish lifts Optima Health target as annual profit beats forecasts
- Optima Health targets further growth after transformational year
- Optima Health trading 'in line' as it continues to grow UK and Ireland platform
- Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
- Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis
- Opthea (NASDAQ:OPT) Stock Price Up 7.2% – Here’s What Happened
- Opthea Provides Corporate Update
- Opthea Announces Decision to Discontinue Wet AMD Trials
Your note
Sign in to keep a note on OPT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Regal Partners Ltd. | 5.40% | 2,907,403 | 10.49M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 4.04% | 2,173,622 | 7.84M | Sep 29, 2024 |
| Millennium Management Llc | 0.13% | 67,392 | 243.18K | Sep 29, 2024 |
| Stratos Wealth Partners, Ltd. | 0.05% | 29,600 | 106.81K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.05% | 26,632 | 96.10K | Sep 29, 2024 |
| Twin Lakes Capital Management, LLC | 0.04% | 19,806 | 71.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| USAA Mutual Fund Tr-Science & Technology Fund | 0.46% | 247,678 | 893.75K | Jul 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 5,049 | 18.22K | Oct 30, 2024 |